GSK paid $85 million up front for global rights to a small-interfering RNA therapy discovered and developed by startup Empirico. The pharmaceutical giant said this drug candidate could be used as a monotherapy and as part of drug combinations for treating COPD and other inflammatory respiratory diseases.
The post GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD appeared first on MedCity News.
